Agile Therapeutics has resubmitted its U.S. marketing application for contraceptive patch Twirla, this follows the company receiving a CRL in December 2017 citing the need for additional adhesion data. Keep this on the watch-list for today and they weeks to come. When this moves it will be fast and frantic.
Analyst Rating Overweight.
3 Buy
2 Hold
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Analyst Rating Overweight.
3 Buy
2 Hold
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Join us on WhatsApp >> dexwirenews.com/WhatsApp
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Join us on WhatsApp >> dexwirenews.com/WhatsApp
4) Follow @DEXWireNews on Social Media